Apogee Therapeutics will report 52-week results from Part A of its Phase 2 APEX trial of Zumilokibart in moderate-to-severe atopic dermatitis today, March 23, 2026, via a company webcast. The readout could meaningfully affect the company’s clinical outlook and share price (potentially ~1-3% move depending on efficacy/safety and any development updates); monitor primary and key secondary endpoints and management commentary.
Apogee Therapeutics will report 52-week results from Part A of its Phase 2 APEX trial of Zumilokibart in moderate-to-severe atopic dermatitis today, March 23, 2026, via a company webcast. The readout could meaningfully affect the company’s clinical outlook and share price (potentially ~1-3% move depending on efficacy/safety and any development updates); monitor primary and key secondary endpoints and management commentary.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
